Category Archives: Cell Therapy

EDMOND, OK--(Marketwire -02/19/12)- The team of veterinarians at White Oaks Veterinary Clinic in Edmond announced that the animal hospital is now offering pet stem cell therapy. This new regenerative medicine for pets helps animals suffering from degenerative joint disease or arthritis. Based on the research and technology provided by a company called Stemlogix, White Oaks Veterinary Clinic can now offer affordable, same-day stem cell therapy to dogs suffering from these debilitating conditions. The Stemlogix technology enables the Edmond veterinarians to extract adult stem cells from a pet's own body fat, virtually eliminating the risk of rejection or negative reaction. "I see far too many otherwise healthy pets at our veterinary clinic that have been hobbled by the effects of arthritis," Dr. Jennifer Bianchi said. "We're thrilled to be able to offer this holistic solution which harnesses the pet's own healing power to aid in the pain relief process. Our main goal with stem cell therapy is to reduce long-term inflammation and slow the progression of cartilage damage. The motto at our veterinary hospital is, 'Quality service at a great value.' Being able to provide stem cell transplants in about two hours at an affordable rate helps us live up to … Continue reading →

16-02-2012 20:19 Many of our patients travel to Guangzhou from all over the world for medical treatment and tourism. China medical tourism can help with becoming a patient, travel arrangements and language assistance. If you want to know more about our services, please browse the web:htttp://www.medicaltourism.hk/ or mail to us: giels-x@medicaltourism.hk firstcare-china@hotmail.com Adult stem cells provide real improvement for cirrhosis patients Breakthrough adult stem cell research has shown that stem cells are able to regenerate and repair damaged or destroyed liver cells. For patients with cirrhosis, this means improved liver function, decreased pain and a significantly improved quality of life. Stem cell therapy offers the safest and most effective treatment alternative for liver cirrhosis and it is quickly becoming a preferred treatment in Asia. China medical tourism offers unique access to the best stem cell therapies available at leading medical facilities. Supporting data and statistics Three out of every four patients treated experienced a significant improvement in their condition following stem cell treatment. The following clinical results were observed: •Improved liver function •Decreased pain •Improved values for liver function, PLT (blood platelet) and blood ammonia You may see improvements during your hospitalization due to neurotrophic factors released during the stem … Continue reading →

GAITHERSBURG, MD--(Marketwire -02/16/12)- Cytomedix, Inc. (OTC.BB: CMXI.OB - News) (the "Company"), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced that Chief Operating Officer Edward L. Field will present a clinical overview of Aldagen's autologous cell therapy technology at two upcoming meetings: The Cell Society's 2nd Annual Clinical Meeting being held February 17-18 at the Coronado Marriott Resort in San Diego; and the 7th Annual New York Stem Cell Summit being held on February 21 at Bridgewaters New York in New York City. Mr. Field will present during the session, "Commercialization Opportunities with Adult Stem Cell Therapies," on Friday, February 17 from 8:00 a.m. to 10:00 a.m. Pacific time at the Cell Society meeting. Cell Society International is a non-profit organization dedicated to advancing the clinical application of adult stem cell therapies worldwide. Cell Society's 2nd Annual Clinical Meeting will continue in the tradition established at the 1st Annual Meeting and will offer a unique opportunity for multidisciplinary, international clinical collaboration designed to enhance understanding and thought-provoking insight into treatments and cures for disease and agonizing medical conditions. This year's clinical focus will center on therapies particularly relevant to cardiology, neurology, and orthopedic … Continue reading →

GAITHERSBURG, MD--(Marketwire -02/16/12)- Cytomedix, Inc. (OTC.BB: CMXI.OB - News) (the "Company"), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced that Chief Operating Officer Edward L. Field will present a clinical overview of Aldagen's autologous cell therapy technology at two upcoming meetings: The Cell Society's 2nd Annual Clinical Meeting being held February 17-18 at the Coronado Marriott Resort in San Diego; and the 7th Annual New York Stem Cell Summit being held on February 21 at Bridgewaters New York in New York City. Mr. Field will present during the session, "Commercialization Opportunities with Adult Stem Cell Therapies," on Friday, February 17 from 8:00 a.m. to 10:00 a.m. Pacific time at the Cell Society meeting. Cell Society International is a non-profit organization dedicated to advancing the clinical application of adult stem cell therapies worldwide. Cell Society's 2nd Annual Clinical Meeting will continue in the tradition established at the 1st Annual Meeting and will offer a unique opportunity for multidisciplinary, international clinical collaboration designed to enhance understanding and thought-provoking insight into treatments and cures for disease and agonizing medical conditions. This year's clinical focus will center on therapies particularly relevant to cardiology, neurology, and orthopedic … Continue reading →

CAMBRIDGE, Mass., Feb. 16, 2012 (GLOBE NEWSWIRE) -- Pathfinder Cell Therapy, Inc. ("Pathfinder," or "the Company") (OTCQB:PFND.PK - News), a biotechnology company focused on the treatment of diseases characterized by organ-specific cell damage, today announced that Richard L. Franklin, M.D., Ph.D., Founder, CEO and President of Pathfinder, will present at the 7th Annual New York Stem Cell Summit being held on Tuesday, February 21, 2012. Event: 7th Annual New York Stem Cell Summit Date: Tuesday, February 21, 2012 Place: Bridgewaters New York, 11 Fulton Street, New York, NY Time: 3:35 pm ET Dr. Franklin will be providing an overview of the Company's novel Pathfinder Cell therapy. The New York Stem Cell Summit brings together stem cell company executives, researchers, investors and physicians to explore investment opportunities in stem cell research and innovation. More information can be found at http://www.stemcellsummit.com. About Pathfinder Pathfinder is developing a novel cell-based therapy and has generated encouraging preclinical data in models of diabetes, renal disease, myocardial infarction, and critical limb ischemia, a severe form of peripheral vascular disease. Leveraging its internal discovery of Pathfinder Cells ("PCs") Pathfinder is pioneering a new field in regenerative medicine. PCs are a newly identified mammalian cell type present in … Continue reading →

CAMBRIDGE, Mass., Feb. 15, 2012 (GLOBE NEWSWIRE) -- Pathfinder Cell Therapy, Inc. ("Pathfinder," or "the Company") (OTCQB:PFND.PK - News), a biotechnology company focused on the treatment of diseases characterized by organ-specific cell damage, today announced that the European Patent Office (EPO) has communicated its intent to grant Pathfinder's first European Patent, EP1896571, which provides intellectual property protection for the Company's cell-based technology throughout this region. The patent covers the Company's proprietary Pathfinder Cells ("PCs"), which are a newly identified non-stem cell mammalian cell type that has demonstrated the ability to stimulate regeneration of local damaged tissue without being incorporated into the new tissue. PCs are being developed by Pathfinder for the treatment of a number of important human diseases and have demonstrated encouraging preclinical results to date, including the ability to completely reverse diabetes in a mouse model (results published in Rejuvenation Research, April 20101). European Patent EP1896571 includes composition of matter claims for the Company's proprietary PCs, as well as methods of use relating to cell-based therapies, specifically for the treatment of diabetes. Richard L. Franklin, M.D., Ph.D., Founder, CEO and President of Pathfinder said, "We are pleased to report the allowance of this critical patent in Europe, which … Continue reading →

14 February 2012 Last updated at 19:10 ET By James Gallagher Health and science reporter, BBC News Bone marrow stem cell therapy offers "moderate improvement" to heart attack patients, according to a large UK review of clinical trials. The analysis by the Cochrane Collaboration looked at 33 trials involving more than 1,700 patients. It said longer-term studies were needed to see if the experimental therapy affected life expectancy. The review comes a day after doctors reported the first case of using heart cells to heal heart attack damage. If a patient survives a heart attack, dead heart muscle is replaced with scar tissue - leaving the patient weaker and possibly on a lifetime of medicine. Researchers are beginning to show that taking cells from a heart, growing millions of new heart cells in the laboratory and pumping those back into the heart may reduce scar tissue and lead to new heart muscle. Continue reading the main story “Start Quote Stem cell therapy may also reduce the number of patients who later die or suffer from heart failure, but currently there is a lack of statistically significant evidence based on the small number of patients treated so far” End Quote Dr … Continue reading →

14 February 2012 Last updated at 19:10 ET By James Gallagher Health and science reporter, BBC News Bone marrow stem cell therapy offers "moderate improvement" to heart attack patients, according to a large UK review of clinical trials. The analysis by the Cochrane Collaboration looked at 33 trials involving more than 1,700 patients. It said longer-term studies were needed to see if the experimental therapy affected life expectancy. The review comes a day after doctors reported the first case of using heart cells to heal heart attack damage. If a patient survives a heart attack, dead heart muscle is replaced with scar tissue - leaving the patient weaker and possibly on a lifetime of medicine. Researchers are beginning to show that taking cells from a heart, growing millions of new heart cells in the laboratory and pumping those back into the heart may reduce scar tissue and lead to new heart muscle. Continue reading the main story “Start Quote Stem cell therapy may also reduce the number of patients who later die or suffer from heart failure, but currently there is a lack of statistically significant evidence based on the small number of patients treated so far” End Quote Dr … Continue reading →

Public release date: 14-Feb-2012 [ | E-mail | Share ] Contact: Jennifer Beal healthnews@wiley.com 44-124-377-0633 Wiley-Blackwell Stem cell therapy moderately improves heart function after a heart attack, according to a systematic review published in The Cochrane Library. But the researchers behind the review say larger clinical trials are needed to establish whether this benefit translates to a longer life. In a heart attack, the blood supply to parts of the heart is cut off by a blocked artery, causing damage to the heart tissue. The cells in the affected area start to die. This is called necrosis and in the days and weeks that follow, the necrotic area may grow, eventually leaving a large part of the heart unable to contract and increasing the risk of further heart problems. Stem cell therapy uses cells from the patient's own bone marrow to try to repair and reduce this damage. Currently, the treatment is only available in facilities with links to scientific research. The authors of the review drew together all the available evidence to ask whether adult bone marrow stem cells can effectively prevent and repair the damage caused by a heart attack. In 2008, a Cochrane review of 13 stem … Continue reading →

February 14, 2012, 3:17 PM EST By Ryan Flinn (Adds comment from researcher in 13th paragraph.) Feb. 14 (Bloomberg) -- Stem cells grown from patients’ own cardiac tissue can heal damage once thought to be permanent after a heart attack, according to a study that suggests the experimental approach may one day help stave off heart failure. In a trial of 25 heart-attack patients, 17 who got the stem cell treatment showed a 50 percent reduction in cardiac scar tissue compared with no improvement for the eight who received standard care. The results, from the first of three sets of clinical trials generally needed for regulatory approval, were published today in the medical journal Lancet. “The findings in this paper are encouraging,” Deepak Srivastava, director of the San Francisco-based Gladstone Institute of Cardiovascular Disease, said in an interview. “There’s a dire need for new therapies for people with heart failure, it’s still the No. 1 cause of death in men and women.” The study, by researchers from Cedars-Sinai Heart Institute in Los Angeles and Johns Hopkins University in Baltimore, tested the approach in patients who recently suffered a heart attack, with the goal that repairing the damage might help stave … Continue reading →